Oral SGLT-2 inhibitors with CV and renal benefits should ideally be prescribed in the high-risk or at-risk T2DM patients but this is counterbalanced by their high costs, making affordability a key parameter against their prescription. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.